Sicor Overview

  • Year Founded
  • 1986

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 174

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $3.4B

Sicor General Information

Description

Manufacturer of generic injectable pharmaceuticals designed for medical treatments. The company utilizes internal research and development capabilities, along with manufacturing and regulatory expertise to produce generic finished-dosage injectable pharmaceuticals and active pharmaceutical ingredients, providing pharmaceutical companies with generic biopharmaceuticals, inhalation ingredients, topical ingredients, and nasal ingredients.

Contact Information

Formerly Known As
Gensia Sicor, Gensia, Gensia Sicor Inc, Gensia Inc, Gensia Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 19 Hughes
  • Irvine, CA 92618
  • United States
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Corporate Office
  • 19 Hughes
  • Irvine, CA 92618
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sicor Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 22-Jan-2004 $3.4B Completed Generating Revenue
4. PIPE 20-May-1997 Completed Generating Revenue
3. IPO 05-Jun-1990 Completed Generating Revenue
2. Corporate 08-Feb-1990 $15M $25.6M Completed Generating Revenue
1. Early Stage VC 05-Sep-1989 $10.6M $10.6M Completed Generating Revenue
To view Sicor’s complete valuation and funding history, request access »

Sicor Patents

Sicor Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2012061469-A2 Crystalline forms of pralatrexate Inactive 02-Nov-2010
WO-2012061469-A3 Crystalline forms of pralatrexate Inactive 02-Nov-2010
WO-2011100325-A2 Polymorphs of sunitinib salts Inactive 09-Feb-2010
WO-2011100325-A3 Polymorphs of sunitinib salts Inactive 09-Feb-2010
EP-2520581-A1 Method for the determination the purity of 5-azacytidine Inactive 06-Aug-2008 C07H1/00
To view Sicor’s complete patent history, request access »

Sicor Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sicor Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
3i Group PE/Buyout Minority
Abingworth Venture Capital Minority
Chancellor Capital Management Venture Capital Minority
Domain Associates Venture Capital Minority
Fairfield Ventures Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Sicor Investments & Acquisitions (2)

Sicor’s most recent deal was a Secondary Transaction - Private with Diaspa for . The deal was made on 01-Jul-1998.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Diaspa 01-Jul-1998 Secondary Transaction - Private Other Commercial Services
Diaspa 29-Dec-1997 Merger/Acquisition Other Commercial Services
To view Sicor’s complete investments and acquisitions history, request access »

Sicor FAQs

  • When was Sicor founded?

    Sicor was founded in 1986.

  • Where is Sicor headquartered?

    Sicor is headquartered in Irvine, CA.

  • What is the size of Sicor?

    Sicor has 174 total employees.

  • What industry is Sicor in?

    Sicor’s primary industry is Pharmaceuticals.

  • Is Sicor a private or public company?

    Sicor is a Private company.

  • What is the current valuation of Sicor?

    The current valuation of Sicor is .

  • What is Sicor’s current revenue?

    The current revenue for Sicor is .

  • How much funding has Sicor raised over time?

    Sicor has raised $76.4M.

  • Who are Sicor’s investors?

    3i Group, Abingworth, Chancellor Capital Management, Domain Associates, and Fairfield Ventures are 5 of 12 investors who have invested in Sicor.

  • When was Sicor acquired?

    Sicor was acquired on 22-Jan-2004.

  • Who acquired Sicor?

    Sicor was acquired by Teva Pharmaceutical Industries.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process